Home/Filings/4/0001213900-20-045810
4//SEC Filing

Rimon Gold Assets Ltd 4

Accession 0001213900-20-045810

CIK 0001218683other

Filed

Dec 30, 7:00 PM ET

Accepted

Dec 31, 5:25 PM ET

Size

25.9 KB

Accession

0001213900-20-045810

Insider Transaction Report

Form 4
Period: 2020-12-29
Transactions
  • Exercise of In-Money

    Common Stock

    2020-12-29+520,8207,877,670 total
  • Exercise of In-Money

    Common Stock

    2020-12-29+3,385,2127,385,060 total
  • Exercise of In-Money

    Warrant (right to buy)

    2020-12-293,385,2120 total
    Exercise: $0.27Exp: 2024-12-12Common Stock (3,385,212 underlying)
  • Sale

    Common Stock

    2020-12-294,3407,873,330 total
  • Exercise of In-Money

    Warrant (right to buy)

    2020-12-29400,0000 total
    Exercise: $0.16From: 2019-04-21Exp: 2023-10-23Common Stock (400,000 underlying)
  • Sale

    Common Stock

    2020-12-2928,2107,356,850 total
  • Sale

    Common Stock

    2020-12-293,0773,999,848 total
  • Exercise of In-Money

    Common Stock

    2020-12-29+400,0004,002,925 total
  • Exercise of In-Money

    Common Stock

    2020-12-29+350,3347,522,996 total
  • Exercise of In-Money

    Warrant (right to buy)

    2020-12-29520,8200 total
    Exercise: $0.16From: 2019-05-31Exp: 2021-05-30Common Stock (520,820 underlying)
  • Sale

    Common Stock

    2020-12-292,9197,520,077 total
  • Exercise of In-Money

    Future Investment Rights

    2020-12-29350,3340 total
    Exercise: $0.27From: 2019-12-13Exp: 2024-12-12Common Stock (350,334 underlying)
Footnotes (6)
  • [F1]On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.
  • [F2]On December 29, 2020 the reporting person exercised a warrant to purchase 400,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 3,077 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 396,923 shares.
  • [F3]On December 29, 2020 the reporting person exercised a warrant to purchase 3,385,212 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 28,210 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 3,357,002 shares.
  • [F4]On December 29, 2020 the reporting person exercised a warrant to purchase 520,820 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 4,340 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 516,480 shares.
  • [F5]On December 29, 2020 the reporting person exercised a warrant to purchase 350,334 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,919 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,415 shares.
  • [F6]Exercisable five days following the public announcement of positive clinical data results for LO2A.

Documents

1 file

Issuer

Wize Pharma, Inc.

CIK 0001218683

Entity typeother

Related Parties

1
  • filerCIK 0001721808

Filing Metadata

Form type
4
Filed
Dec 30, 7:00 PM ET
Accepted
Dec 31, 5:25 PM ET
Size
25.9 KB